These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38305113)

  • 21. Quality of life, work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil.
    Parra RS; Chebli JMF; Amarante HMBS; Flores C; Parente JML; Ramos O; Fernandes M; Rocha JJR; Feitosa MR; Feres O; Scotton AS; Nones RB; Lima MM; Zaltman C; Goncalves CD; Guimaraes IM; Santana GO; Sassaki LY; Hossne RS; Bafutto M; Junior RLK; Faria MAG; Miszputen SJ; Gomes TNF; Catapani WR; Faria AA; Souza SCS; Caratin RF; Senra JT; Ferrari MLA
    World J Gastroenterol; 2019 Oct; 25(38):5862-5882. PubMed ID: 31636478
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum adipokines in inflammatory bowel disease.
    Waluga M; Hartleb M; Boryczka G; Kukla M; Zwirska-Korczala K
    World J Gastroenterol; 2014 Jun; 20(22):6912-7. PubMed ID: 24944482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
    Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
    World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mucosal Expression of Type 2 and Type 17 Immune Response Genes Distinguishes Ulcerative Colitis From Colon-Only Crohn's Disease in Treatment-Naive Pediatric Patients.
    Rosen MJ; Karns R; Vallance JE; Bezold R; Waddell A; Collins MH; Haberman Y; Minar P; Baldassano RN; Hyams JS; Baker SS; Kellermayer R; Noe JD; Griffiths AM; Rosh JR; Crandall WV; Heyman MB; Mack DR; Kappelman MD; Markowitz J; Moulton DE; Leleiko NS; Walters TD; Kugathasan S; Wilson KT; Hogan SP; Denson LA
    Gastroenterology; 2017 May; 152(6):1345-1357.e7. PubMed ID: 28132889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease.
    Farias E Silva K; Nanini HF; Cascabulho CM; Rosas SLB; Santana PT; Carneiro AJV; Anaissie E; Nucci M; de Souza HSP
    World J Gastroenterol; 2021 Mar; 27(9):866-885. PubMed ID: 33727775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world treatment patterns and disease control over one year in patients with inflammatory bowel disease in Brazil.
    Sassaki LY; Miszputen SJ; Kaiser Junior RL; Catapani WR; Bafutto M; Scotton AS; Zaltman C; Baima JP; Ramos HS; Faria MAG; Gonçalves CD; Guimaraes IM; Flores C; Amarante HMBS; Nones RB; Parente JML; Lima MM; Chebli JM; Ferrari MLA; Campos JF; Sanna MGP; Ramos O; Parra RS; da Rocha JJR; Feres O; Feitosa MR; Caratin RF; Senra JT; Santana GO
    World J Gastroenterol; 2021 Jun; 27(23):3396-3412. PubMed ID: 34163120
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.
    Abenavoli L; Spagnuolo R; Scarlata GGM; Scarpellini E; Boccuto L; Luzza F
    Medicina (Kaunas); 2023 Nov; 59(11):. PubMed ID: 38003983
    [No Abstract]   [Full Text] [Related]  

  • 28. Helminth therapy (worms) for induction of remission in inflammatory bowel disease.
    Garg SK; Croft AM; Bager P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD009400. PubMed ID: 24442917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sleep disturbance and risk of active disease in patients with Crohn's disease and ulcerative colitis.
    Ananthakrishnan AN; Long MD; Martin CF; Sandler RS; Kappelman MD
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):965-71. PubMed ID: 23376797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of Vitamin D in Patients with Inflammatory Bowel Disease Treated with Vedolizumab.
    Abraham BP; Fan C; Thurston T; Moskow J; Malaty HM
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004241
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel disease-associated spondyloarthritis.
    Luchetti MM; Ciccia F; Avellini C; Benfaremo D; Rizzo A; Spadoni T; Svegliati S; Marzioni D; Santinelli A; Costantini A; Viola N; Berretta A; Ciferri M; Mattioli Belmonte Cima M; Mosca P; Benedetti A; Gabrielli A
    Rheumatology (Oxford); 2021 Jan; 60(1):92-102. PubMed ID: 32442267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4+ immune response as a potential biomarker of patient reported inflammatory bowel disease (IBD) activity.
    Brandhorst G; Weigand S; Eberle C; Raddatz D; Karaus M; Oellerich M; Walson PD
    Clin Chim Acta; 2013 Jun; 421():31-3. PubMed ID: 23485644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease.
    Kader HA; Tchernev VT; Satyaraj E; Lejnine S; Kotler G; Kingsmore SF; Patel DD
    Am J Gastroenterol; 2005 Feb; 100(2):414-23. PubMed ID: 15667502
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.
    Plevy S; Silverberg MS; Lockton S; Stockfisch T; Croner L; Stachelski J; Brown M; Triggs C; Chuang E; Princen F; Singh S
    Inflamm Bowel Dis; 2013 May; 19(6):1139-48. PubMed ID: 23518807
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating markers of gut barrier function associated with disease severity in primary sclerosing cholangitis.
    Dhillon AK; Kummen M; Trøseid M; Åkra S; Liaskou E; Moum B; Vesterhus M; Karlsen TH; Seljeflot I; Hov JR
    Liver Int; 2019 Feb; 39(2):371-381. PubMed ID: 30269440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum galectins as potential biomarkers of inflammatory bowel diseases.
    Yu TB; Dodd S; Yu LG; Subramanian S
    PLoS One; 2020; 15(1):e0227306. PubMed ID: 31929564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
    Nikolaus S; Schulte B; Al-Massad N; Thieme F; Schulte DM; Bethge J; Rehman A; Tran F; Aden K; Häsler R; Moll N; Schütze G; Schwarz MJ; Waetzig GH; Rosenstiel P; Krawczak M; Szymczak S; Schreiber S
    Gastroenterology; 2017 Dec; 153(6):1504-1516.e2. PubMed ID: 28827067
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases.
    Korkmaz H; Asıl M; Temel T; Öztürk B; Kebapçılar L
    Turk J Med Sci; 2021 Oct; 51(5):2403-2412. PubMed ID: 33984894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
    Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
    Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.
    ; ; Bousvaros A; Antonioli DA; Colletti RB; Dubinsky MC; Glickman JN; Gold BD; Griffiths AM; Jevon GP; Higuchi LM; Hyams JS; Kirschner BS; Kugathasan S; Baldassano RN; Russo PA
    J Pediatr Gastroenterol Nutr; 2007 May; 44(5):653-74. PubMed ID: 17460505
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.